Kelly Covello, Ph.D. joined Mirati in April 2020 as Vice President, Head of Medical Affairs, bringing in more than 15 years of oncology pharmaceutical industry experience in diverse R&D roles spanning drug discovery, clinical development, and medical strategy.
Before joining Mirati, Dr. Covello held numerous roles of increasing responsibilities at Bristol-Myers Squibb, GlaxoSmithKline, and Boehringer Ingelheim. She was a Senior Early Development Team Lead responsible for the early development strategy of a portfolio of immuno-oncology assets. She also served as the Global Medical Lead for Lung Cancer and led the medical team to develop and execute the medical communication and non-registrational data generation strategy for Opdivo® and Yervoy®.
Dr. Covello’s experience also includes medical lead roles for Erbitux® and Gilotrif® and has led launch preparations for nivolumab across 5 indications, and the mage-a3 cancer vaccine for melanoma and NSCLC.
Dr. Covello received her B.S. in Biology from The College of New Jersey and earned her Ph.D., Cell and Molecular Biology from the University of Pennsylvania Medical School.
March 10, 2022
Today The Biotech Project chats with Kelly Covello, PhD who has extensive experience in Medical Affairs. She currently serves as the head of a medical affairs organization at a well respected biotech. Kelly offers her pers…